



Article Title

First Author^{1,*}, Co-Author² and Co-Author²

¹Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

²Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

Correspondence*:

corresponding Author

Laboratory X, Institute X, Department X, Organization X, Street X, City X, State XX (only USA, Canada and Australia), Zip Code, X Country X, email@uni.edu

2 ABSTRACT

3 Refer to

4 <http://www.frontiersin.org/Bioengineering/authorguidelines>
5 or **Table1** for abstract requirement and length according to article type.

6 **Keywords:** Text Text Text Text Text Text Text Text

1 INTRODUCTION

7 Text
8 Text. Text
9 Text. Text
10 Text. Text
11 Text.

2 MATERIAL & METHODS

12 Text
13 Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text. **LastName1 et al.** (2013) might want to know
14 about text text text text Text Text Text Text Text Text Text Text Text Text. (**OtherAuthor and**
15 **Coauthor**, 2012) might want to know about text text text text Text Text Text Text Text Text Text Text Text
16 Text
17 Text Text Text. **Author4 and Author5** (2013) might want to know about text text text text

18 Please note that very large tables (covering several pages) cannot be included in the final PDF for reasons
19 of space. These tables will be published as supplementary material on the online article abstract page at
20 the time of acceptance. The author will notified during the typesetting of the final article if this is the case.
21 A link in the final PDF will direct to the online material.

Table 1. Maximum size of the Manuscript

	Abstract max. length (incl. spaces)	Figures or tables	Manuscript max. length	Final PDF length
Clinical Case Study				
Clinical Trial				
Hypothesis and Theory				
Methods	2000 characters	15	12000 words	12 pages
Original Research				
Review				
Technology Report				
Focused Review	2000 characters	5	5000 words	5 pages
CPC	1250 characters	6	2500 words	4 pages
Perspective	1250 characters	2	3000 words	3 pages
Mini Review				
Classification	1250 characters	10	2000 words	12 pages
Editorial	none	none	1000 words	1 page
Book review				
Frontiers Commentary	none	1	1000 words	1 page
General Commentary				
Field Grand Challenge				
Opinion	none	1	2000 words	2 pages
Specialty Grand Challenge				

2.1 ORIGINAL RESEARCH ARTICLES, CLINICAL TRIAL ARTICLES, AND TECHNOLOGY REPORTS

For Original Research Articles, Clinical Trial Articles, and Technology Reports the section headings should be those appropriate for your field and the research itself. It is recommended to organize your manuscript in the following sections or their equivalents for your field:

- Introduction: Succinct, with no subheadings.
- Materials and Methods: This section may be divided by subheadings. This section should contain sufficient detail so that when read in conjunction with cited references, all procedures can be repeated.
- Results: This section may be divided by subheadings. Footnotes should not be used and have to be transferred into the main text.
- Discussion: This section may be divided by subheadings. Discussions should cover the key findings of the study: discuss any prior art related to the subject so to place the novelty of the discovery in the appropriate context; discuss the potential short-comings and limitations on their interpretations; discuss their integration into the current understanding of the problem and how this advances the current views; speculate on the future direction of the research and freely postulate theories that could be tested in the future.

Please note that the Material and Methods section can be placed in any of the following ways: before Results, before Discussion or after Discussion.

2.2 CLINICAL CASE STUDIES

For Clinical Case Studies the following sections are mandatory:

- Introduction: Include symptoms at presentation, physical exams and lab results.

Table 2. Resolution Requirements for the figures

Image Type	Description	Format	Color Mode	Resolution
Line Art	An image composed of lines and text, which does not contain tonal or shaded areas.	TIFF, JPEG	RGB, Bitmap	900 - 1200 dpi
Halftone	A continuous tone photograph, which contains no text.	TIFF, EPS, JPEG	RGB, Grayscale	300 dpi
Combination	Image contains halftone + text or line art elements.	TIFF, JPEG	RGB, Grayscale	600 - 900 dpi

- 40 • Background: This section may be divided by subheadings. Include history and review of similar cases.
41 • Results: This section may be divided by subheadings. Include diagnosis and treatment.
42 • Concluding Remarks

3 RESULTS

Frontiers requires figures to be submitted individually, in the same order as they are referred to in the manuscript. Figures will then be automatically embedded at the bottom of the submitted manuscript. Kindly ensure that each table and figure is mentioned in the text and in numerical order. Permission must be obtained for use of copyrighted material from other sources (including the web). Please note that it is compulsory to follow figure instructions. Figures which are not according to the guidelines will cause substantial delay during the production process.

$$\sum x + y = Z \quad (1)$$

49 **Table2** shows the resolution requirements for the figures. The figures must be legible:

1. The smallest visible text is no less than 8 points in height, when viewed at actual size.
2. Solid lines are not broken up.
3. Image areas are not pixelated or stair stepped.
4. Text is legible and of high quality.
5. Any lines in the graphic are no smaller than 2 points width.
6. The actual size of the figure must be of at least 8.5 cm.

4 DISCUSSION

56 Text
57 Text Text Text Text. Additional Requirements:

4.1 CORRECTIONS

58 Minor corrections to published articles can be communicated to the Frontiers Production Office at produ-
59 ction.office@frontiersin.org. If you need to communicate important changes to an article please submit a
60 General Commentary. Submit the article with the title Erratum: Original Title of Article.

4.2 COMMENTARIES ON ARTICLES

61 At the beginning of your manuscript provide the citation of the article commented on.

4.3 FOCUSED REVIEWS

62 For Tier 2 invited Focused Reviews the sections Introduction, Material and Methods, Results, and Discus-
63 sion are recommended. In addition the authors must submit a short biography of the corresponding
64 author(s). This short biography has a maximum of 600 characters, including spaces.

65 A picture (5 x 5 cm, in *.tif or *.jpg, min 300 dpi) must be submitted along with the biography in
66 the manuscript and separately during figure upload. Focused Reviews highlight and explain key concepts
67 of your work. Please highlight a minimum of four and a maximum of ten key concepts in bold in your
68 manuscript and provide the definitions/explanations at the end of your manuscript under Key Concepts.
69 Each definition has a maximum of 400 characters, including spaces.

4.4 HUMAN SEARCH AND ANIMAL RESEARCH

70 All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant
71 institutional and national guidelines and regulations. In the manuscript, authors must identify the commit-
72 tee approving the experiments and must confirm that all experiments conform to the relevant regulatory
73 standards. For manuscripts reporting experiments on human subjects, authors must identify the committee
74 approving the experiments and must also include a statement confirming that informed consent was obtain-
75 ed from all subjects. In Original Research Articles and Clinical Trial Articles these statements should
76 appear in the Materials and Methods section.

4.5 CLINICAL TRIAL REGISTRATION

77 Clinical trials should be registered in a public trials registry in order to become the object of a publication
78 at Frontiers. Trials must be registered at or before the start of patient enrollment. A clinical trial is defined
79 as "any research study that prospectively assigns human participants or groups of humans to one or more
80 health-related interventions to evaluate the effects on health outcomes." (www.who.int/ict rp/en).
81 A list of acceptable registries can be found at www.who.int/ict rp/en and www.icmje.org.

4.6 INCLUSION OF PROTEOMICS DATA

82 Authors should provide relevant information relating to how the peptide/protein matches were underta-
83 ken, including methods used to process and analyze data, false discovery rates (FDR) for large-scale
84 studies and threshold or cut-off rates for peptide and protein matches. Further information could include
85 software used, mass spectrometer type, sequence database and version, number of sequences in database,
86 processing methods, mass tolerances used for matching, variable/fixed modifications, allowable missed
87 cleavages, etc.

88 Authors should provide as supplementary material information used to identify proteins and/or pepti-
89 des. This should include information such as accession numbers, observed mass (m/z), charge, delta mass,
90 matched mass, peptide/protein scores, peptide modification, miscleavages, peptide sequence, match rank,
91 matched species (for cross species matching), number of peptide matches, ambiguous protein/peptide
92 matches should be indicated, etc. For quantitative proteomics analyses authors should provide informa-
93 tion to justify the statistical significance including biological replicates, statistical methods, estimates of
94 uncertainty and the methods used for calculating error.

95 For peptide matches with biologically relevant post-translational modifications (PTM) and for any pro-
96 tein match that has occurred using a single mass spectrum, authors should include this information as raw

97 data, annotated spectra or submit data to an online repository (recommended option). Authors are encour-
98 aged to submit raw or matched data and 2-DE images to public proteomics repositories. Submission
99 codes and/or links to data should be provided within the manuscript.

4.7 DATA SHARING

100 Frontiers supports the policy of data sharing, and authors are advised to make freely available any materi-
101 als and information described in their article, and any data relevant to the article (while not compromising
102 confidentiality in the context of human-subject research) that may be reasonably requested by others for
103 the purpose of academic and non-commercial research. In regards to deposition of data and data sharing
104 through databases, Frontiers urges authors to comply with the current best practices within their discipline.

DISCLOSURE/CONFLICT-OF-INTEREST STATEMENT

105 The authors declare that the research was conducted in the absence of any commercial or financial
106 relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

107 The statement about the authors and contributors can be up to several sentences long, describing the tasks
108 of individual authors referred to by their initials and should be included at the end of the manuscript before
109 the References section.

ACKNOWLEDGEMENT

110 Text
111 Text Text Text Text Text.

112 *Funding:* Text Text Text Text Text Text Text Text.

SUPPLEMENTAL DATA

113 Text
114 Text Text Text Text Text Text.

REFERENCES

115 Author4, N. and Author5, N. (2013), Title of the article, *Frontiers in Neurorobotics*, 7, 25, doi:10.3389/
116 fnbot.2013.56789
117 LastName1, A., LastName2, A., and LastName2, A. (2013), Article title, *Frontiers in Neuroscience*, 30,
118 30, 10127–10134, doi:10.3389/fnins.2013.12345
119 OtherAuthor, N. and Coauthor, N. S. (2012), Article title, *Frontiers in Genetics*, 30, 49, 16417–16418,
120 doi:10.3389/fgene.2012.54321

FIGURES

121 **Figure 1.** Enter the caption for your figure here. Repeat as necessary for each of your figures.